AstraZeneca (LSE:AZN) has seen a shift recently with the EU approval of ENHERTU® and Imfinzi®, which are likely influential ...

The European Commission (EC) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for use as a ...

AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the European Commission (EC) to ...

Daiichi Sankyo (DSNKY) and AstraZeneca’s Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hor ...

Enhertu gains EU approval for treating advanced breast cancer with low HER2 levels, marking a milestone for Daiichi Sankyo & ...

Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...

London open The FTSE 100 is expected to open six points lower on Friday, having closed down 1.55% on Thursday at 8,474.74.

AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and ...

Breast cancer drug Enhurtu costs about £8,000 each session and is only available privately in England, but it is offered on ...

The data is also a big relief for AZ, which paid a hefty $1.4 billion upfront to license rights to Enhertu in a deal that could be worth up to $6.9 billion to Daiichi Sankyo if all the ADC's ...